Ganirelix
Also known as: Antagon, Ganirelix, Ganirelix acetate, Orgalutran, RS-26306
Source Ganirelix at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ganirelix is a synthetic decapeptide GnRH antagonist used in assisted reproductive technology to prevent premature LH surge during controlled ovarian stimulation.
Mechanism of Action
Competitive antagonist at pituitary GnRH receptors, suppressing LH and FSH secretion
Routes of Administration
Goals & Uses
- Reduction of ovarian hyperstimulation syndrome (OHSS) riskSafety In ARTModerate
- Prevent premature LH surgeReproductiveHigh
- Treatment of endometriosisGynecologyLow
- Controlled ovarian hyperstimulation for IVFAssisted Reproductive TechnologyHigh
- Prostate cancer (androgen deprivation)OncologyLow
- Prevention of premature LH surge during COHReproductive EndocrinologyHigh
Contraindications
- Severe renal or hepatic impairmentOrgan ImpairmentModerate
- Hypersensitivity to ganirelix or any component of the formulationAllergyHigh
- Hypersensitivity to ganirelix or any componentAllergyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Known hypersensitivity to GnRH or GnRH analogsAllergyHigh
Adverse Effects
- Injection site reactionsLocalCommon
- Hypersensitivity/anaphylaxisImmunologicalRare
- HeadacheNeurologicUncommonPain in the head or upper neck
- Abdominal pain/pelvic painGastrointestinal/reproductiveCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Hot flushesVasomotorCommon
- Ovarian hyperstimulation syndrome (OHSS)ReproductiveUncommon
Drug Interactions
- Human Chorionic Gonadotropin (hCG)Low
- Gonadotropins (FSH, hMG)Low
- GnRH agonistsHigh
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Hepatic impairmentOrgan FunctionRelative
- Renal impairmentOrgan ImpairmentRelative
- Women undergoing IVFReproductiveRelative
- Pediatric patientsAgeAbsolute
- Postmenopausal womenReproductive StatusAbsolute
Regulatory Status
- European UnionApprovedApproved: controlled ovarian stimulation in IVFAuthorized in member states.
- United StatesApprovedApproved: controlled ovarian stimulation in IVFMarketed as Orgalutran.
- United KingdomApprovedApproved: controlled ovarian stimulation in IVF
Approved in the US (FDA) and EU for use in IVF protocols; marketed under the brand name Orgalutran.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Ganirelix?
Ganirelix is a synthetic decapeptide GnRH antagonist used in assisted reproductive technology to prevent premature LH surge during controlled ovarian stimulation.
What is Ganirelix used for?
Ganirelix is educationally associated with: Reduction of ovarian hyperstimulation syndrome (OHSS) risk, Prevent premature LH surge, Treatment of endometriosis, Controlled ovarian hyperstimulation for IVF, Prostate cancer (androgen deprivation), Prevention of premature LH surge during COH. Educational only — not medical advice.
How is Ganirelix administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Ganirelix?
Reported adverse effects include: Injection site reactions, Hypersensitivity/anaphylaxis, Headache, Abdominal pain/pelvic pain, Nausea, Hot flushes, Ovarian hyperstimulation syndrome (OHSS). This list is not exhaustive — consult a qualified clinician.
Who should avoid Ganirelix?
Recorded contraindications: Severe renal or hepatic impairment, Hypersensitivity to ganirelix or any component of the formulation, Hypersensitivity to ganirelix or any component, Pregnancy, Known hypersensitivity to GnRH or GnRH analogs. Consult a qualified clinician before use.